Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.

Celltrion's biosimilar Avtozma, used to treat inflammatory diseases, was approved for the U.S. market by the Food and Drug Administration.

Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday its new biosimilar for an autoimmune disease treatment has received approval from the U.S. Food and Drug Administration (FDA).

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

Celltrion has applied for an extension of the marketing authorisation to cover the inflammatory bowel disease indication, with an approval expected in mid-2020.

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions ...

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...